SOPH (Sophia Genetics) Current Deferred Revenue: $15.62 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SOPH Sophia Genetics SA SOPH
71 GF Score
Price $6.52
GF Value $5.10
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics Current Deferred Revenue?

Sophia Genetics SOPH -4.68% 71 Current Deferred Revenue is $15.62 Mil as of Jun. 2026. GuruFocus rates SOPH with a GF Score™ of 71/100 and a GF Value™ of $5.10 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Sophia Genetics's current deferred revenue for the quarter that ended in Jun. 2026 was $15.62 Mil.

Sophia Genetics Current Deferred Revenue Related Terms

Sophia Genetics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics Current Deferred Revenue Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 4.07 3.43 9.49 5.73 16.72

Sophia Genetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.65 10.04 16.72 15.95 15.62
SOPH
71GF Score
Sophia Genetics SA SOPH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $15.62 Mil mean?
Sophia Genetics (SOPH) has a Current Deferred Revenue of $15.62 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sophia Genetics and its competitors.
Is Sophia Genetics' Current Deferred Revenue too high?
Sophia Genetics' current Current Deferred Revenue is $15.62 Mil. Overall, Sophia Genetics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Current Deferred Revenue compare to EVH and NRC?
Sophia Genetics' Current Deferred Revenue of $15.62 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Sophia Genetics and its competitors. Sophia Genetics's current Current Deferred Revenue is $15.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.10, compared to a current price of $6.52 — trading 27.8% above its estimated fair value. The current Current Deferred Revenue is $15.62 Mil. Sophia Genetics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Current Deferred Revenue is $15.62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (SOPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of $6.52 is trading 27.8% above its estimated GF Value™ of $5.10. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for SOPH:

  • Current Deferred Revenue: $15.62 Mil
  • GF Value™: $5.10 vs. price of $6.52 (27.8% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Other Exchanges 90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
71GF Score

Get the complete analysis for SOPH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.52
Price
$5.10
GF Value